New drug combo shows promise in tough lung cancer trial

NCT ID NCT04063163

Completed Disease control Sponsor: Shanghai Henlius Biotech Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated May 07, 2026 · Updated 18 times

Summary

This phase 3 trial tested whether adding the experimental drug HLX10 to standard chemotherapy helps people with extensive-stage small cell lung cancer live longer. About 585 participants who had not received prior treatment were randomly assigned to get either HLX10 plus chemo or a placebo plus chemo. The study measured overall survival and tumor response to see if the new combination works better.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Arkhangelsk Clinical Oncology Dispensary

Arkhangelsk, Russia
Institute for Personalized Medicine

Tbilisi, Georgia
Komunalnyi zaklad Miska bahato

Dnipropetrovsk, Ukraine
Medipol Mega Hospital

Istanbul, Turkey (Türkiye)
Wojew. Wielospecjalistyczne Centrum Onkologii i Traumatologi

Lodz, Poland

Conditions

Explore the condition pages connected to this study.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER